Stifel Nicolaus reaffirmed their buy rating on shares of Concert Pharmaceuticals (NASDAQ:CNCE) in a research report released on Friday. Stifel Nicolaus currently has a $27.00 target price on the biotechnology company’s stock.
Several other equities research analysts have also recently issued reports on CNCE. Zacks Investment Research cut shares of Concert Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, September 15th. HC Wainwright reiterated a buy rating and set a $20.00 price target on shares of Concert Pharmaceuticals in a research report on Monday, September 18th. Mizuho initiated coverage on shares of Concert Pharmaceuticals in a research report on Thursday, October 26th. They set a buy rating and a $23.00 price target for the company. Finally, TheStreet upgraded shares of Concert Pharmaceuticals from a d rating to a c+ rating in a research report on Wednesday, November 29th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $24.33.
Concert Pharmaceuticals (NASDAQ CNCE) traded down $7.53 during trading on Friday, reaching $20.15. 3,408,205 shares of the company traded hands, compared to its average volume of 468,920. Concert Pharmaceuticals has a 52-week low of $8.61 and a 52-week high of $30.71. The firm has a market capitalization of $458.87, a PE ratio of 5.37 and a beta of 1.67.
Several institutional investors and hedge funds have recently made changes to their positions in CNCE. SG Americas Securities LLC purchased a new position in shares of Concert Pharmaceuticals in the third quarter valued at approximately $153,000. Alliancebernstein L.P. purchased a new position in shares of Concert Pharmaceuticals in the second quarter valued at approximately $174,000. State of Wisconsin Investment Board purchased a new position in shares of Concert Pharmaceuticals in the second quarter valued at approximately $181,000. Princeton Capital Management Inc. purchased a new position in shares of Concert Pharmaceuticals in the third quarter valued at approximately $215,000. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Concert Pharmaceuticals by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 287 shares during the period. Institutional investors and hedge funds own 65.29% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Stifel Nicolaus Reiterates Buy Rating for Concert Pharmaceuticals (CNCE)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2018/01/13/stifel-nicolaus-reiterates-buy-rating-for-concert-pharmaceuticals-cnce.html.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.